1.Bone marrow involvement by primary oxalosis
Stefano FRATONI ; Pasquale NISCOLA
Blood Research 2020;55(4):192-192
2.Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Andrea TENDAS ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2013;48(4):297-298
No abstract available.
Splenectomy*
;
Thrombocytopenia*
3.Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Pasquale NISCOLA ; Massimiliano PALOMBI ; Stefano FRATONI ; Alessio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2013;48(4):296-297
No abstract available.
Aged*
;
B-Lymphocytes*
;
Bone Marrow*
;
Cyclophosphamide*
;
Doxorubicin*
;
Humans
;
Lymphoma, B-Cell*
;
Prednisone*
;
Vincristine*
;
Rituximab
4.Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Pasquale NISCOLA ; Alessio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2013;48(4):292-293
No abstract available.
Anemia, Hemolytic, Autoimmune*
;
Female
;
Humans
;
Venous Thrombosis*
5.Hematologists and nephrologists working together: moving forward with a new integrated care model for blood-related malignancies?.
Pasquale NISCOLA ; Tommaso CARAVITA ; Paola TATANGELO ; Agostina SINISCALCHI ; Paolo DE FABRITIIS ; Roberto PALUMBO
Blood Research 2017;52(3):218-219
No abstract available.
6.Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2015;50(2):113-114
No abstract available.
Azacitidine*
;
Humans
7.Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2013;48(2):152-153
No abstract available.
Leukemia, Myelomonocytic, Chronic
;
Myelodysplastic Syndromes
8.Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Roberta MEROLA ; Gianfranco CATALANO ; Paolo DE FABRITIIS
Blood Research 2014;49(2):130-137
No abstract available.
Humans
9.Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab.
Andrea TENDAS ; Pasquale NISCOLA ; Laura SCARAMUCCI ; Luca CUPELLI ; Alessio Pio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2016;51(2):137-138
No abstract available.
Red-Cell Aplasia, Pure*
;
Rituximab*
10.Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?.
Massimiliano PALOMBI ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Malgorzata Monika TRAWINSKA ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2016;51(1):66-66
No abstract available.
Thrombocytopenia*
;
Rituximab